Fmr LLC decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 11.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,291,458 shares of the medical equipment provider’s stock after selling 289,116 shares during the quarter. Fmr LLC’s holdings in Hologic were worth $91,085,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in HOLX. Piedmont Investment Advisors LLC acquired a new position in Hologic during the second quarter worth $127,000. Amussen Hunsaker Associates LLC acquired a new stake in Hologic in the second quarter valued at $159,000. Homrich & Berg acquired a new stake in Hologic in the second quarter valued at $204,000. Granite Springs Asset Management LLC acquired a new stake in Hologic in the second quarter valued at $206,000. Finally, BerganKDV Wealth Management LLC acquired a new stake in Hologic in the second quarter valued at $269,000. Institutional investors and hedge funds own 98.74% of the company’s stock.
A number of analysts have commented on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $50.00 price target on shares of Hologic in a research note on Wednesday, August 1st. Canaccord Genuity cut their price target on shares of Hologic from $42.00 to $41.00 and set a “hold” rating for the company in a research note on Tuesday, August 14th. TheStreet cut shares of Hologic from a “b-” rating to a “c+” rating in a research note on Wednesday, September 5th. BidaskClub upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research note on Saturday, September 15th. Finally, Morgan Stanley cut their price target on shares of Hologic from $47.00 to $44.00 and set an “equal weight” rating for the company in a research note on Thursday, October 11th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $44.41.
Shares of HOLX opened at $41.78 on Friday. The stock has a market capitalization of $11.23 billion, a PE ratio of 18.74, a P/E/G ratio of 1.88 and a beta of 0.65. Hologic, Inc. has a fifty-two week low of $35.10 and a fifty-two week high of $45.09. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, November 7th. The medical equipment provider reported $0.58 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.01). The company had revenue of $813.50 million during the quarter, compared to the consensus estimate of $808.63 million. Hologic had a negative net margin of 3.46% and a positive return on equity of 22.93%. Hologic’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.50 earnings per share. Equities research analysts anticipate that Hologic, Inc. will post 2.4 EPS for the current fiscal year.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: Hedge Funds – Risk or Reward?
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.